nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—lung cancer—liver cancer	0.297	1	CtDrD
Crizotinib—TNK2—liver cancer	0.137	0.533	CbGaD
Crizotinib—MET—liver cancer	0.0736	0.286	CbGaD
Crizotinib—ABL1—liver cancer	0.0464	0.181	CbGaD
Crizotinib—CDK7—Sorafenib—liver cancer	0.0457	0.145	CbGbCtD
Crizotinib—MUSK—Sorafenib—liver cancer	0.0457	0.145	CbGbCtD
Crizotinib—AURKA—Epirubicin—liver cancer	0.0378	0.12	CbGbCtD
Crizotinib—TAOK2—Sorafenib—liver cancer	0.0331	0.105	CbGbCtD
Crizotinib—TIE1—Sorafenib—liver cancer	0.0331	0.105	CbGbCtD
Crizotinib—AURKA—Doxorubicin—liver cancer	0.0201	0.0638	CbGbCtD
Crizotinib—FLT3—Sorafenib—liver cancer	0.019	0.0604	CbGbCtD
Crizotinib—EPHA6—Sorafenib—liver cancer	0.0168	0.0534	CbGbCtD
Crizotinib—EPHB6—Sorafenib—liver cancer	0.0168	0.0534	CbGbCtD
Crizotinib—STK10—Sorafenib—liver cancer	0.0151	0.048	CbGbCtD
Crizotinib—CSF1R—Sorafenib—liver cancer	0.0151	0.048	CbGbCtD
Crizotinib—MAP3K19—Sorafenib—liver cancer	0.0126	0.0401	CbGbCtD
Crizotinib—Drug-induced liver injury—Sorafenib—liver cancer	0.00378	0.114	CcSEcCtD
Crizotinib—Disease progression—Sorafenib—liver cancer	0.00181	0.0545	CcSEcCtD
Crizotinib—Gastrointestinal perforation—Sorafenib—liver cancer	0.00152	0.0456	CcSEcCtD
Crizotinib—Peripheral sensory neuropathy—Sorafenib—liver cancer	0.00139	0.0417	CcSEcCtD
Crizotinib—CYP3A5—Sorafenib—liver cancer	0.00138	0.00439	CbGbCtD
Crizotinib—ABCB1—Sorafenib—liver cancer	0.000899	0.00286	CbGbCtD
Crizotinib—Lymphopenia—Sorafenib—liver cancer	0.000774	0.0233	CcSEcCtD
Crizotinib—PRKD3—embryo—liver cancer	0.000731	0.041	CbGeAlD
Crizotinib—Hypophosphataemia—Sorafenib—liver cancer	0.000682	0.0205	CcSEcCtD
Crizotinib—MET—embryo—liver cancer	0.000632	0.0355	CbGeAlD
Crizotinib—ACVR1B—embryo—liver cancer	0.000585	0.0328	CbGeAlD
Crizotinib—Haemoglobin decreased—Sorafenib—liver cancer	0.000576	0.0173	CcSEcCtD
Crizotinib—Interstitial lung disease—Sorafenib—liver cancer	0.00056	0.0168	CcSEcCtD
Crizotinib—DCLK1—embryo—liver cancer	0.000554	0.0311	CbGeAlD
Crizotinib—ABCB1—Doxorubicin—liver cancer	0.000545	0.00173	CbGbCtD
Crizotinib—CYP3A4—Sorafenib—liver cancer	0.000538	0.00171	CbGbCtD
Crizotinib—ALK—embryo—liver cancer	0.000517	0.029	CbGeAlD
Crizotinib—Peripheral sensory neuropathy—Epirubicin—liver cancer	0.000512	0.0154	CcSEcCtD
Crizotinib—IGF1R—embryo—liver cancer	0.000497	0.0279	CbGeAlD
Crizotinib—Peripheral sensory neuropathy—Doxorubicin—liver cancer	0.000474	0.0142	CcSEcCtD
Crizotinib—Polyneuropathy—Epirubicin—liver cancer	0.000449	0.0135	CcSEcCtD
Crizotinib—Polyneuropathy—Doxorubicin—liver cancer	0.000416	0.0125	CcSEcCtD
Crizotinib—PTK2B—embryo—liver cancer	0.000401	0.0225	CbGeAlD
Crizotinib—NEK9—liver—liver cancer	0.000386	0.0216	CbGeAlD
Crizotinib—EPHA4—embryo—liver cancer	0.000384	0.0215	CbGeAlD
Crizotinib—Neuropathy—Sorafenib—liver cancer	0.000372	0.0112	CcSEcCtD
Crizotinib—PTK2—embryo—liver cancer	0.000369	0.0207	CbGeAlD
Crizotinib—RPS6KB1—embryo—liver cancer	0.000355	0.0199	CbGeAlD
Crizotinib—FGR—embryo—liver cancer	0.000353	0.0198	CbGeAlD
Crizotinib—SIK2—liver—liver cancer	0.000347	0.0195	CbGeAlD
Crizotinib—Dysaesthesia—Epirubicin—liver cancer	0.000339	0.0102	CcSEcCtD
Crizotinib—PRKD3—liver—liver cancer	0.000338	0.019	CbGeAlD
Crizotinib—JAK2—embryo—liver cancer	0.000333	0.0187	CbGeAlD
Crizotinib—Hepatic function abnormal—Sorafenib—liver cancer	0.000329	0.00989	CcSEcCtD
Crizotinib—CYP3A4—Doxorubicin—liver cancer	0.000327	0.00104	CbGbCtD
Crizotinib—CASK—liver—liver cancer	0.000323	0.0181	CbGeAlD
Crizotinib—TEK—embryo—liver cancer	0.000321	0.018	CbGeAlD
Crizotinib—Hepatic failure—Sorafenib—liver cancer	0.00032	0.00962	CcSEcCtD
Crizotinib—Dysaesthesia—Doxorubicin—liver cancer	0.000313	0.00941	CcSEcCtD
Crizotinib—FES—liver—liver cancer	0.000309	0.0173	CbGeAlD
Crizotinib—MET—liver—liver cancer	0.000292	0.0164	CbGeAlD
Crizotinib—Lymphopenia—Epirubicin—liver cancer	0.000286	0.0086	CcSEcCtD
Crizotinib—SRC—embryo—liver cancer	0.000285	0.016	CbGeAlD
Crizotinib—CDK7—liver—liver cancer	0.000283	0.0159	CbGeAlD
Crizotinib—TAOK2—liver—liver cancer	0.000281	0.0157	CbGeAlD
Crizotinib—ACVR1B—liver—liver cancer	0.00027	0.0152	CbGeAlD
Crizotinib—Lymphopenia—Doxorubicin—liver cancer	0.000265	0.00796	CcSEcCtD
Crizotinib—Hypokalaemia—Sorafenib—liver cancer	0.000262	0.00787	CcSEcCtD
Crizotinib—Aspartate aminotransferase increased—Sorafenib—liver cancer	0.000259	0.00778	CcSEcCtD
Crizotinib—CSF1R—embryo—liver cancer	0.000256	0.0144	CbGeAlD
Crizotinib—Alanine aminotransferase increased—Sorafenib—liver cancer	0.000254	0.00762	CcSEcCtD
Crizotinib—STK4—liver—liver cancer	0.000253	0.0142	CbGeAlD
Crizotinib—Hypophosphataemia—Epirubicin—liver cancer	0.000252	0.00757	CcSEcCtD
Crizotinib—Generalised oedema—Epirubicin—liver cancer	0.000246	0.0074	CcSEcCtD
Crizotinib—Febrile neutropenia—Epirubicin—liver cancer	0.000243	0.00732	CcSEcCtD
Crizotinib—Transaminases increased—Epirubicin—liver cancer	0.000241	0.00723	CcSEcCtD
Crizotinib—FER—liver—liver cancer	0.000239	0.0134	CbGeAlD
Crizotinib—LYN—liver—liver cancer	0.000238	0.0133	CbGeAlD
Crizotinib—TNK1—liver—liver cancer	0.000237	0.0133	CbGeAlD
Crizotinib—Hypophosphataemia—Doxorubicin—liver cancer	0.000233	0.00701	CcSEcCtD
Crizotinib—Neutropenia—Sorafenib—liver cancer	0.000232	0.00699	CcSEcCtD
Crizotinib—TNK2—liver—liver cancer	0.00023	0.0129	CbGeAlD
Crizotinib—IGF1R—liver—liver cancer	0.00023	0.0129	CbGeAlD
Crizotinib—Generalised oedema—Doxorubicin—liver cancer	0.000228	0.00685	CcSEcCtD
Crizotinib—MAP4K2—liver—liver cancer	0.000227	0.0127	CbGeAlD
Crizotinib—Febrile neutropenia—Doxorubicin—liver cancer	0.000225	0.00677	CcSEcCtD
Crizotinib—Weight decreased—Sorafenib—liver cancer	0.000225	0.00676	CcSEcCtD
Crizotinib—STK3—liver—liver cancer	0.000224	0.0125	CbGeAlD
Crizotinib—TIE1—liver—liver cancer	0.000224	0.0125	CbGeAlD
Crizotinib—Pneumonia—Sorafenib—liver cancer	0.000223	0.0067	CcSEcCtD
Crizotinib—Transaminases increased—Doxorubicin—liver cancer	0.000223	0.00669	CcSEcCtD
Crizotinib—Infestation NOS—Sorafenib—liver cancer	0.000222	0.00666	CcSEcCtD
Crizotinib—Infestation—Sorafenib—liver cancer	0.000222	0.00666	CcSEcCtD
Crizotinib—AURKA—liver—liver cancer	0.000218	0.0122	CbGeAlD
Crizotinib—Neuropathy peripheral—Sorafenib—liver cancer	0.000217	0.00653	CcSEcCtD
Crizotinib—TESK1—liver—liver cancer	0.000216	0.0121	CbGeAlD
Crizotinib—Neuralgia—Epirubicin—liver cancer	0.000211	0.00633	CcSEcCtD
Crizotinib—Burning sensation—Epirubicin—liver cancer	0.000211	0.00633	CcSEcCtD
Crizotinib—MERTK—liver—liver cancer	0.00021	0.0118	CbGeAlD
Crizotinib—Hepatobiliary disease—Sorafenib—liver cancer	0.00021	0.0063	CcSEcCtD
Crizotinib—LIMK2—liver—liver cancer	0.000206	0.0115	CbGeAlD
Crizotinib—NUAK2—liver—liver cancer	0.000205	0.0115	CbGeAlD
Crizotinib—FLT3—liver—liver cancer	0.000203	0.0114	CbGeAlD
Crizotinib—MAP3K12—liver—liver cancer	0.000203	0.0114	CbGeAlD
Crizotinib—ACVR1—liver—liver cancer	0.000203	0.0114	CbGeAlD
Crizotinib—ABL1—embryo—liver cancer	0.000203	0.0114	CbGeAlD
Crizotinib—STK35—liver—liver cancer	0.000199	0.0112	CbGeAlD
Crizotinib—Urinary tract disorder—Sorafenib—liver cancer	0.000197	0.00591	CcSEcCtD
Crizotinib—Urethral disorder—Sorafenib—liver cancer	0.000195	0.00586	CcSEcCtD
Crizotinib—Neuralgia—Doxorubicin—liver cancer	0.000195	0.00586	CcSEcCtD
Crizotinib—Burning sensation—Doxorubicin—liver cancer	0.000195	0.00586	CcSEcCtD
Crizotinib—ABL2—liver—liver cancer	0.000194	0.0109	CbGeAlD
Crizotinib—BMP2K—liver—liver cancer	0.000192	0.0108	CbGeAlD
Crizotinib—PTK2B—liver—liver cancer	0.000185	0.0104	CbGeAlD
Crizotinib—Abscess—Epirubicin—liver cancer	0.000185	0.00556	CcSEcCtD
Crizotinib—Cardiac disorder—Sorafenib—liver cancer	0.000185	0.00555	CcSEcCtD
Crizotinib—RIPK2—liver—liver cancer	0.000184	0.0103	CbGeAlD
Crizotinib—Mediastinal disorder—Sorafenib—liver cancer	0.000179	0.00539	CcSEcCtD
Crizotinib—Arrhythmia—Sorafenib—liver cancer	0.000178	0.00534	CcSEcCtD
Crizotinib—MAP3K2—liver—liver cancer	0.000174	0.00977	CbGeAlD
Crizotinib—Malnutrition—Sorafenib—liver cancer	0.000173	0.00521	CcSEcCtD
Crizotinib—Abscess—Doxorubicin—liver cancer	0.000171	0.00515	CcSEcCtD
Crizotinib—PTK2—liver—liver cancer	0.000171	0.00957	CbGeAlD
Crizotinib—TBK1—liver—liver cancer	0.000171	0.00957	CbGeAlD
Crizotinib—Dysgeusia—Sorafenib—liver cancer	0.00017	0.0051	CcSEcCtD
Crizotinib—TYK2—liver—liver cancer	0.000169	0.0095	CbGeAlD
Crizotinib—IRAK1—liver—liver cancer	0.000167	0.00938	CbGeAlD
Crizotinib—RPS6KB1—liver—liver cancer	0.000164	0.0092	CbGeAlD
Crizotinib—FGR—liver—liver cancer	0.000163	0.00915	CbGeAlD
Crizotinib—LCK—liver—liver cancer	0.000163	0.00915	CbGeAlD
Crizotinib—AXL—liver—liver cancer	0.000162	0.00911	CbGeAlD
Crizotinib—Anaemia—Sorafenib—liver cancer	0.00016	0.00481	CcSEcCtD
Crizotinib—SLK—liver—liver cancer	0.000156	0.00877	CbGeAlD
Crizotinib—Syncope—Sorafenib—liver cancer	0.000155	0.00467	CcSEcCtD
Crizotinib—EPHB4—liver—liver cancer	0.000155	0.00871	CbGeAlD
Crizotinib—Leukopenia—Sorafenib—liver cancer	0.000155	0.00466	CcSEcCtD
Crizotinib—JAK2—liver—liver cancer	0.000154	0.00864	CbGeAlD
Crizotinib—EPHA2—liver—liver cancer	0.000152	0.00854	CbGeAlD
Crizotinib—Loss of consciousness—Sorafenib—liver cancer	0.000152	0.00458	CcSEcCtD
Crizotinib—Gait disturbance—Epirubicin—liver cancer	0.00015	0.00451	CcSEcCtD
Crizotinib—MAP4K5—liver—liver cancer	0.000149	0.00833	CbGeAlD
Crizotinib—MAP3K3—liver—liver cancer	0.000149	0.00833	CbGeAlD
Crizotinib—TEK—liver—liver cancer	0.000149	0.00833	CbGeAlD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.000146	0.0044	CcSEcCtD
Crizotinib—Pulmonary embolism—Epirubicin—liver cancer	0.000146	0.0044	CcSEcCtD
Crizotinib—Phosphatase alkaline increased—Epirubicin—liver cancer	0.000146	0.0044	CcSEcCtD
Crizotinib—Infection—Sorafenib—liver cancer	0.00014	0.00422	CcSEcCtD
Crizotinib—Shock—Sorafenib—liver cancer	0.000139	0.00418	CcSEcCtD
Crizotinib—Fluid retention—Epirubicin—liver cancer	0.000139	0.00418	CcSEcCtD
Crizotinib—Gait disturbance—Doxorubicin—liver cancer	0.000139	0.00417	CcSEcCtD
Crizotinib—Nervous system disorder—Sorafenib—liver cancer	0.000139	0.00417	CcSEcCtD
Crizotinib—Neuropathy—Epirubicin—liver cancer	0.000137	0.00413	CcSEcCtD
Crizotinib—Skin disorder—Sorafenib—liver cancer	0.000137	0.00413	CcSEcCtD
Crizotinib—YES1—liver—liver cancer	0.000137	0.00769	CbGeAlD
Crizotinib—STK10—liver—liver cancer	0.000136	0.00763	CbGeAlD
Crizotinib—Phosphatase alkaline increased—Doxorubicin—liver cancer	0.000136	0.00407	CcSEcCtD
Crizotinib—Pulmonary embolism—Doxorubicin—liver cancer	0.000136	0.00407	CcSEcCtD
Crizotinib—TAOK3—liver—liver cancer	0.000135	0.0076	CbGeAlD
Crizotinib—SRC—liver—liver cancer	0.000132	0.0074	CbGeAlD
Crizotinib—Fluid retention—Doxorubicin—liver cancer	0.000129	0.00387	CcSEcCtD
Crizotinib—Neuropathy—Doxorubicin—liver cancer	0.000127	0.00382	CcSEcCtD
Crizotinib—Sepsis—Epirubicin—liver cancer	0.000127	0.00382	CcSEcCtD
Crizotinib—Dyspnoea—Sorafenib—liver cancer	0.000126	0.00379	CcSEcCtD
Crizotinib—Dyspepsia—Sorafenib—liver cancer	0.000124	0.00374	CcSEcCtD
Crizotinib—Decreased appetite—Sorafenib—liver cancer	0.000123	0.00369	CcSEcCtD
Crizotinib—Blood alkaline phosphatase increased—Epirubicin—liver cancer	0.000122	0.00367	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Sorafenib—liver cancer	0.000122	0.00367	CcSEcCtD
Crizotinib—Fatigue—Sorafenib—liver cancer	0.000122	0.00366	CcSEcCtD
Crizotinib—Hepatic function abnormal—Epirubicin—liver cancer	0.000122	0.00366	CcSEcCtD
Crizotinib—Constipation—Sorafenib—liver cancer	0.000121	0.00363	CcSEcCtD
Crizotinib—CSF1R—liver—liver cancer	0.000119	0.00665	CbGeAlD
Crizotinib—Hepatic failure—Epirubicin—liver cancer	0.000118	0.00355	CcSEcCtD
Crizotinib—Sepsis—Doxorubicin—liver cancer	0.000118	0.00353	CcSEcCtD
Crizotinib—IGF1R—Idarubicin—Epirubicin—liver cancer	0.000116	0.0739	CbGdCrCtD
Crizotinib—Blood alkaline phosphatase increased—Doxorubicin—liver cancer	0.000113	0.0034	CcSEcCtD
Crizotinib—Hepatic function abnormal—Doxorubicin—liver cancer	0.000113	0.00338	CcSEcCtD
Crizotinib—Body temperature increased—Sorafenib—liver cancer	0.000112	0.00336	CcSEcCtD
Crizotinib—Hepatic failure—Doxorubicin—liver cancer	0.000109	0.00329	CcSEcCtD
Crizotinib—IGF1R—Idarubicin—Doxorubicin—liver cancer	0.000107	0.0684	CbGdCrCtD
Crizotinib—Diplopia—Epirubicin—liver cancer	0.000106	0.00319	CcSEcCtD
Crizotinib—Face oedema—Epirubicin—liver cancer	0.000103	0.00308	CcSEcCtD
Crizotinib—Asthenia—Sorafenib—liver cancer	0.000101	0.00305	CcSEcCtD
Crizotinib—Diplopia—Doxorubicin—liver cancer	9.84e-05	0.00296	CcSEcCtD
Crizotinib—Hypokalaemia—Epirubicin—liver cancer	9.67e-05	0.00291	CcSEcCtD
Crizotinib—Diarrhoea—Sorafenib—liver cancer	9.67e-05	0.00291	CcSEcCtD
Crizotinib—Aspartate aminotransferase increased—Epirubicin—liver cancer	9.57e-05	0.00288	CcSEcCtD
Crizotinib—Face oedema—Doxorubicin—liver cancer	9.5e-05	0.00285	CcSEcCtD
Crizotinib—Muscular weakness—Epirubicin—liver cancer	9.38e-05	0.00282	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Epirubicin—liver cancer	9.38e-05	0.00282	CcSEcCtD
Crizotinib—ABL1—liver—liver cancer	9.37e-05	0.00525	CbGeAlD
Crizotinib—Dizziness—Sorafenib—liver cancer	9.35e-05	0.00281	CcSEcCtD
Crizotinib—CDK7—Idarubicin—Epirubicin—liver cancer	9.34e-05	0.0596	CbGdCrCtD
Crizotinib—CDK7—Doxorubicin—Epirubicin—liver cancer	9.34e-05	0.0596	CbGdCrCtD
Crizotinib—CDK7—Daunorubicin—Epirubicin—liver cancer	9.34e-05	0.0596	CbGdCrCtD
Crizotinib—Vomiting—Sorafenib—liver cancer	8.99e-05	0.0027	CcSEcCtD
Crizotinib—Hypokalaemia—Doxorubicin—liver cancer	8.95e-05	0.00269	CcSEcCtD
Crizotinib—Rash—Sorafenib—liver cancer	8.91e-05	0.00268	CcSEcCtD
Crizotinib—Dermatitis—Sorafenib—liver cancer	8.91e-05	0.00268	CcSEcCtD
Crizotinib—Aspartate aminotransferase increased—Doxorubicin—liver cancer	8.86e-05	0.00266	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Doxorubicin—liver cancer	8.67e-05	0.00261	CcSEcCtD
Crizotinib—Muscular weakness—Doxorubicin—liver cancer	8.67e-05	0.00261	CcSEcCtD
Crizotinib—CDK7—Epirubicin—Doxorubicin—liver cancer	8.64e-05	0.0551	CbGdCrCtD
Crizotinib—CDK7—Idarubicin—Doxorubicin—liver cancer	8.64e-05	0.0551	CbGdCrCtD
Crizotinib—CDK7—Daunorubicin—Doxorubicin—liver cancer	8.64e-05	0.0551	CbGdCrCtD
Crizotinib—Neutropenia—Epirubicin—liver cancer	8.59e-05	0.00258	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Epirubicin—liver cancer	8.54e-05	0.00257	CcSEcCtD
Crizotinib—Nausea—Sorafenib—liver cancer	8.4e-05	0.00252	CcSEcCtD
Crizotinib—Weight decreased—Epirubicin—liver cancer	8.31e-05	0.0025	CcSEcCtD
Crizotinib—Pneumonia—Epirubicin—liver cancer	8.24e-05	0.00248	CcSEcCtD
Crizotinib—Infestation—Epirubicin—liver cancer	8.19e-05	0.00246	CcSEcCtD
Crizotinib—Infestation NOS—Epirubicin—liver cancer	8.19e-05	0.00246	CcSEcCtD
Crizotinib—Neuropathy peripheral—Epirubicin—liver cancer	8.03e-05	0.00241	CcSEcCtD
Crizotinib—Neutropenia—Doxorubicin—liver cancer	7.95e-05	0.00239	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Doxorubicin—liver cancer	7.9e-05	0.00237	CcSEcCtD
Crizotinib—Hepatobiliary disease—Epirubicin—liver cancer	7.75e-05	0.00233	CcSEcCtD
Crizotinib—Weight decreased—Doxorubicin—liver cancer	7.69e-05	0.00231	CcSEcCtD
Crizotinib—Pneumonia—Doxorubicin—liver cancer	7.62e-05	0.00229	CcSEcCtD
Crizotinib—Infestation—Doxorubicin—liver cancer	7.58e-05	0.00228	CcSEcCtD
Crizotinib—Infestation NOS—Doxorubicin—liver cancer	7.58e-05	0.00228	CcSEcCtD
Crizotinib—Bradycardia—Epirubicin—liver cancer	7.49e-05	0.00225	CcSEcCtD
Crizotinib—Neuropathy peripheral—Doxorubicin—liver cancer	7.43e-05	0.00223	CcSEcCtD
Crizotinib—Hypoaesthesia—Epirubicin—liver cancer	7.32e-05	0.0022	CcSEcCtD
Crizotinib—Urinary tract disorder—Epirubicin—liver cancer	7.26e-05	0.00218	CcSEcCtD
Crizotinib—Oedema peripheral—Epirubicin—liver cancer	7.24e-05	0.00218	CcSEcCtD
Crizotinib—Urethral disorder—Epirubicin—liver cancer	7.21e-05	0.00217	CcSEcCtD
Crizotinib—Hepatobiliary disease—Doxorubicin—liver cancer	7.17e-05	0.00215	CcSEcCtD
Crizotinib—Visual impairment—Epirubicin—liver cancer	7.09e-05	0.00213	CcSEcCtD
Crizotinib—Bradycardia—Doxorubicin—liver cancer	6.93e-05	0.00208	CcSEcCtD
Crizotinib—Eye disorder—Epirubicin—liver cancer	6.87e-05	0.00207	CcSEcCtD
Crizotinib—Cardiac disorder—Epirubicin—liver cancer	6.83e-05	0.00205	CcSEcCtD
Crizotinib—Hypoaesthesia—Doxorubicin—liver cancer	6.77e-05	0.00203	CcSEcCtD
Crizotinib—Urinary tract disorder—Doxorubicin—liver cancer	6.72e-05	0.00202	CcSEcCtD
Crizotinib—Oedema peripheral—Doxorubicin—liver cancer	6.7e-05	0.00201	CcSEcCtD
Crizotinib—Urethral disorder—Doxorubicin—liver cancer	6.67e-05	0.002	CcSEcCtD
Crizotinib—Mediastinal disorder—Epirubicin—liver cancer	6.63e-05	0.00199	CcSEcCtD
Crizotinib—Arrhythmia—Epirubicin—liver cancer	6.57e-05	0.00197	CcSEcCtD
Crizotinib—Visual impairment—Doxorubicin—liver cancer	6.56e-05	0.00197	CcSEcCtD
Crizotinib—Malnutrition—Epirubicin—liver cancer	6.4e-05	0.00192	CcSEcCtD
Crizotinib—Eye disorder—Doxorubicin—liver cancer	6.36e-05	0.00191	CcSEcCtD
Crizotinib—Cardiac disorder—Doxorubicin—liver cancer	6.32e-05	0.0019	CcSEcCtD
Crizotinib—ABCB1—embryo—liver cancer	6.3e-05	0.00353	CbGeAlD
Crizotinib—Dysgeusia—Epirubicin—liver cancer	6.27e-05	0.00188	CcSEcCtD
Crizotinib—Mediastinal disorder—Doxorubicin—liver cancer	6.13e-05	0.00184	CcSEcCtD
Crizotinib—PLK4—Doxorubicin—Epirubicin—liver cancer	6.08e-05	0.0388	CbGdCrCtD
Crizotinib—PLK4—Idarubicin—Epirubicin—liver cancer	6.08e-05	0.0388	CbGdCrCtD
Crizotinib—Arrhythmia—Doxorubicin—liver cancer	6.08e-05	0.00183	CcSEcCtD
Crizotinib—Vision blurred—Epirubicin—liver cancer	6.03e-05	0.00181	CcSEcCtD
Crizotinib—Malnutrition—Doxorubicin—liver cancer	5.92e-05	0.00178	CcSEcCtD
Crizotinib—Anaemia—Epirubicin—liver cancer	5.92e-05	0.00178	CcSEcCtD
Crizotinib—Dysgeusia—Doxorubicin—liver cancer	5.8e-05	0.00174	CcSEcCtD
Crizotinib—Syncope—Epirubicin—liver cancer	5.74e-05	0.00173	CcSEcCtD
Crizotinib—Leukopenia—Epirubicin—liver cancer	5.73e-05	0.00172	CcSEcCtD
Crizotinib—PLK4—Idarubicin—Doxorubicin—liver cancer	5.63e-05	0.0359	CbGdCrCtD
Crizotinib—PLK4—Epirubicin—Doxorubicin—liver cancer	5.63e-05	0.0359	CbGdCrCtD
Crizotinib—Loss of consciousness—Epirubicin—liver cancer	5.63e-05	0.00169	CcSEcCtD
Crizotinib—Vision blurred—Doxorubicin—liver cancer	5.58e-05	0.00168	CcSEcCtD
Crizotinib—CYP3A5—liver—liver cancer	5.48e-05	0.00308	CbGeAlD
Crizotinib—Anaemia—Doxorubicin—liver cancer	5.47e-05	0.00165	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	5.41e-05	0.00163	CcSEcCtD
Crizotinib—Syncope—Doxorubicin—liver cancer	5.31e-05	0.0016	CcSEcCtD
Crizotinib—Leukopenia—Doxorubicin—liver cancer	5.3e-05	0.00159	CcSEcCtD
Crizotinib—Oedema—Epirubicin—liver cancer	5.22e-05	0.00157	CcSEcCtD
Crizotinib—Loss of consciousness—Doxorubicin—liver cancer	5.21e-05	0.00156	CcSEcCtD
Crizotinib—Infection—Epirubicin—liver cancer	5.19e-05	0.00156	CcSEcCtD
Crizotinib—Shock—Epirubicin—liver cancer	5.14e-05	0.00154	CcSEcCtD
Crizotinib—Nervous system disorder—Epirubicin—liver cancer	5.12e-05	0.00154	CcSEcCtD
Crizotinib—ABL1—Daunorubicin—Epirubicin—liver cancer	5.11e-05	0.0326	CbGdCrCtD
Crizotinib—ABL1—Doxorubicin—Epirubicin—liver cancer	5.11e-05	0.0326	CbGdCrCtD
Crizotinib—ABL1—Idarubicin—Epirubicin—liver cancer	5.11e-05	0.0326	CbGdCrCtD
Crizotinib—Skin disorder—Epirubicin—liver cancer	5.07e-05	0.00153	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	5.01e-05	0.0015	CcSEcCtD
Crizotinib—Oedema—Doxorubicin—liver cancer	4.83e-05	0.00145	CcSEcCtD
Crizotinib—Infection—Doxorubicin—liver cancer	4.8e-05	0.00144	CcSEcCtD
Crizotinib—AURKA—Idarubicin—Epirubicin—liver cancer	4.76e-05	0.0304	CbGdCrCtD
Crizotinib—AURKA—Daunorubicin—Epirubicin—liver cancer	4.76e-05	0.0304	CbGdCrCtD
Crizotinib—AURKA—Doxorubicin—Epirubicin—liver cancer	4.76e-05	0.0304	CbGdCrCtD
Crizotinib—Shock—Doxorubicin—liver cancer	4.76e-05	0.00143	CcSEcCtD
Crizotinib—Nervous system disorder—Doxorubicin—liver cancer	4.74e-05	0.00142	CcSEcCtD
Crizotinib—ABL1—Epirubicin—Doxorubicin—liver cancer	4.73e-05	0.0302	CbGdCrCtD
Crizotinib—ABL1—Idarubicin—Doxorubicin—liver cancer	4.73e-05	0.0302	CbGdCrCtD
Crizotinib—ABL1—Daunorubicin—Doxorubicin—liver cancer	4.73e-05	0.0302	CbGdCrCtD
Crizotinib—Skin disorder—Doxorubicin—liver cancer	4.7e-05	0.00141	CcSEcCtD
Crizotinib—Paraesthesia—Epirubicin—liver cancer	4.69e-05	0.00141	CcSEcCtD
Crizotinib—Dyspnoea—Epirubicin—liver cancer	4.66e-05	0.0014	CcSEcCtD
Crizotinib—Dyspepsia—Epirubicin—liver cancer	4.6e-05	0.00138	CcSEcCtD
Crizotinib—Decreased appetite—Epirubicin—liver cancer	4.54e-05	0.00136	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Epirubicin—liver cancer	4.51e-05	0.00136	CcSEcCtD
Crizotinib—Fatigue—Epirubicin—liver cancer	4.5e-05	0.00135	CcSEcCtD
Crizotinib—Constipation—Epirubicin—liver cancer	4.47e-05	0.00134	CcSEcCtD
Crizotinib—AURKA—Idarubicin—Doxorubicin—liver cancer	4.41e-05	0.0281	CbGdCrCtD
Crizotinib—AURKA—Daunorubicin—Doxorubicin—liver cancer	4.41e-05	0.0281	CbGdCrCtD
Crizotinib—AURKA—Epirubicin—Doxorubicin—liver cancer	4.41e-05	0.0281	CbGdCrCtD
Crizotinib—Paraesthesia—Doxorubicin—liver cancer	4.34e-05	0.0013	CcSEcCtD
Crizotinib—Dyspnoea—Doxorubicin—liver cancer	4.31e-05	0.0013	CcSEcCtD
Crizotinib—Dyspepsia—Doxorubicin—liver cancer	4.26e-05	0.00128	CcSEcCtD
Crizotinib—Decreased appetite—Doxorubicin—liver cancer	4.2e-05	0.00126	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Doxorubicin—liver cancer	4.17e-05	0.00125	CcSEcCtD
Crizotinib—Fatigue—Doxorubicin—liver cancer	4.17e-05	0.00125	CcSEcCtD
Crizotinib—Constipation—Doxorubicin—liver cancer	4.13e-05	0.00124	CcSEcCtD
Crizotinib—Body temperature increased—Epirubicin—liver cancer	4.13e-05	0.00124	CcSEcCtD
Crizotinib—CYP3A4—liver—liver cancer	4.12e-05	0.00231	CbGeAlD
Crizotinib—Body temperature increased—Doxorubicin—liver cancer	3.82e-05	0.00115	CcSEcCtD
Crizotinib—Asthenia—Epirubicin—liver cancer	3.75e-05	0.00113	CcSEcCtD
Crizotinib—Diarrhoea—Epirubicin—liver cancer	3.57e-05	0.00107	CcSEcCtD
Crizotinib—Asthenia—Doxorubicin—liver cancer	3.47e-05	0.00104	CcSEcCtD
Crizotinib—Dizziness—Epirubicin—liver cancer	3.45e-05	0.00104	CcSEcCtD
Crizotinib—Vomiting—Epirubicin—liver cancer	3.32e-05	0.000998	CcSEcCtD
Crizotinib—Diarrhoea—Doxorubicin—liver cancer	3.31e-05	0.000994	CcSEcCtD
Crizotinib—Rash—Epirubicin—liver cancer	3.29e-05	0.00099	CcSEcCtD
Crizotinib—Dermatitis—Epirubicin—liver cancer	3.29e-05	0.000989	CcSEcCtD
Crizotinib—Dizziness—Doxorubicin—liver cancer	3.2e-05	0.000961	CcSEcCtD
Crizotinib—Nausea—Epirubicin—liver cancer	3.1e-05	0.000933	CcSEcCtD
Crizotinib—Vomiting—Doxorubicin—liver cancer	3.07e-05	0.000924	CcSEcCtD
Crizotinib—Rash—Doxorubicin—liver cancer	3.05e-05	0.000916	CcSEcCtD
Crizotinib—Dermatitis—Doxorubicin—liver cancer	3.05e-05	0.000915	CcSEcCtD
Crizotinib—ABCB1—liver—liver cancer	2.91e-05	0.00163	CbGeAlD
Crizotinib—Nausea—Doxorubicin—liver cancer	2.87e-05	0.000863	CcSEcCtD
Crizotinib—IRAK1—Signaling Pathways—VEGFA—liver cancer	3.63e-07	4.61e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—F2—liver cancer	3.62e-07	4.59e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—STAT3—liver cancer	3.6e-07	4.56e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GSTP1—liver cancer	3.59e-07	4.56e-06	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—AKT1—liver cancer	3.59e-07	4.55e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—STAT3—liver cancer	3.59e-07	4.55e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—HRAS—liver cancer	3.58e-07	4.54e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MYC—liver cancer	3.57e-07	4.53e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TGFB1—liver cancer	3.56e-07	4.52e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—CDKN1B—liver cancer	3.56e-07	4.51e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—CDKN1A—liver cancer	3.56e-07	4.51e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—HMOX1—liver cancer	3.54e-07	4.49e-06	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—AKT1—liver cancer	3.54e-07	4.49e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—PIK3CA—liver cancer	3.54e-07	4.48e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—PIK3CA—liver cancer	3.53e-07	4.48e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TP53—liver cancer	3.53e-07	4.47e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—VEGFA—liver cancer	3.53e-07	4.47e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—HRAS—liver cancer	3.52e-07	4.47e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MYC—liver cancer	3.52e-07	4.47e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TGFB1—liver cancer	3.52e-07	4.46e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—KRAS—liver cancer	3.51e-07	4.46e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—MYC—liver cancer	3.51e-07	4.45e-06	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—AKT1—liver cancer	3.51e-07	4.45e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—RAF1—liver cancer	3.51e-07	4.45e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—TGFB1—liver cancer	3.5e-07	4.44e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—STAT3—liver cancer	3.49e-07	4.43e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—IL6—liver cancer	3.48e-07	4.42e-06	CbGpPWpGaD
Crizotinib—TYK2—Immune System—AKT1—liver cancer	3.48e-07	4.41e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—MAPK8—liver cancer	3.47e-07	4.4e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—APC—liver cancer	3.47e-07	4.39e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3CG—liver cancer	3.47e-07	4.39e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—PIK3CA—liver cancer	3.45e-07	4.38e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PIK3CD—liver cancer	3.44e-07	4.36e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—PIK3CA—liver cancer	3.43e-07	4.35e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CDKN1B—liver cancer	3.43e-07	4.35e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MTOR—liver cancer	3.42e-07	4.34e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PIK3CB—liver cancer	3.42e-07	4.34e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—IL6—liver cancer	3.42e-07	4.34e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TP53—liver cancer	3.42e-07	4.34e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—SERPINE1—liver cancer	3.4e-07	4.32e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—IL6—liver cancer	3.37e-07	4.28e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—HRAS—liver cancer	3.37e-07	4.28e-06	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—AKT1—liver cancer	3.37e-07	4.28e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CASP3—liver cancer	3.37e-07	4.27e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—CTNNB1—liver cancer	3.36e-07	4.26e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL2—liver cancer	3.36e-07	4.26e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MYC—liver cancer	3.34e-07	4.24e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TGFB1—liver cancer	3.33e-07	4.23e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—STAT3—liver cancer	3.31e-07	4.2e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GSTM1—liver cancer	3.3e-07	4.19e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—KRAS—liver cancer	3.3e-07	4.19e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—HPGDS—liver cancer	3.29e-07	4.18e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—CDKN1A—liver cancer	3.28e-07	4.16e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CCND1—liver cancer	3.28e-07	4.15e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—HRAS—liver cancer	3.27e-07	4.15e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—HRAS—liver cancer	3.27e-07	4.15e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—JUN—liver cancer	3.27e-07	4.15e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—BRAF—liver cancer	3.26e-07	4.13e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—KRAS—liver cancer	3.26e-07	4.13e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CG—liver cancer	3.25e-07	4.12e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MYC—liver cancer	3.24e-07	4.11e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—KRAS—liver cancer	3.24e-07	4.11e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CTNNB1—liver cancer	3.24e-07	4.11e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TGFB1—liver cancer	3.24e-07	4.1e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—PIK3CA—liver cancer	3.23e-07	4.09e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—IL6—liver cancer	3.23e-07	4.09e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CDKN1B—liver cancer	3.21e-07	4.08e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—AKT1—liver cancer	3.21e-07	4.07e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—HRAS—liver cancer	3.19e-07	4.05e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MMP9—liver cancer	3.18e-07	4.03e-06	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—AKT1—liver cancer	3.18e-07	4.03e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—HRAS—liver cancer	3.18e-07	4.03e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—STAT3—liver cancer	3.17e-07	4.02e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CDKN1A—liver cancer	3.17e-07	4.02e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—AKT1—liver cancer	3.16e-07	4e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CASP3—liver cancer	3.15e-07	3.99e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL2—liver cancer	3.14e-07	3.99e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PPARG—liver cancer	3.14e-07	3.98e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—IL6—liver cancer	3.13e-07	3.97e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CYP1A1—liver cancer	3.13e-07	3.97e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—IL6—liver cancer	3.13e-07	3.97e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—AKT1—liver cancer	3.11e-07	3.95e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MAPK8—liver cancer	3.09e-07	3.92e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—KRAS—liver cancer	3.09e-07	3.92e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—KRAS—liver cancer	3.08e-07	3.9e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—MYC—liver cancer	3.08e-07	3.9e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—RAF1—liver cancer	3.07e-07	3.9e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—TGFB1—liver cancer	3.07e-07	3.89e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CCND1—liver cancer	3.07e-07	3.89e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—JUN—liver cancer	3.06e-07	3.88e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL6—liver cancer	3.06e-07	3.87e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3CD—liver cancer	3.05e-07	3.86e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL6—liver cancer	3.04e-07	3.86e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CTNNB1—liver cancer	3.04e-07	3.85e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—PIK3CA—liver cancer	3.03e-07	3.85e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—SERPINE1—liver cancer	3.01e-07	3.82e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MTOR—liver cancer	3e-07	3.8e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PIK3CB—liver cancer	3e-07	3.8e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—KRAS—liver cancer	3e-07	3.8e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—PIK3CA—liver cancer	2.99e-07	3.79e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—HRAS—liver cancer	2.99e-07	3.79e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—PIK3CA—liver cancer	2.98e-07	3.78e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—AKT1—liver cancer	2.98e-07	3.78e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MMP9—liver cancer	2.98e-07	3.77e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CDKN1A—liver cancer	2.97e-07	3.76e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PSMD10—liver cancer	2.93e-07	3.72e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PSMA4—liver cancer	2.93e-07	3.72e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TP53—liver cancer	2.93e-07	3.72e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—STAT3—liver cancer	2.93e-07	3.72e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—MTHFR—liver cancer	2.92e-07	3.7e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MAPK8—liver cancer	2.89e-07	3.67e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TP53—liver cancer	2.89e-07	3.67e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—AKT1—liver cancer	2.89e-07	3.66e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—AKT1—liver cancer	2.89e-07	3.66e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PPARA—liver cancer	2.86e-07	3.63e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL6—liver cancer	2.86e-07	3.63e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CD—liver cancer	2.86e-07	3.62e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—VEGFA—liver cancer	2.86e-07	3.62e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GOT2—liver cancer	2.86e-07	3.62e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—KRAS—liver cancer	2.84e-07	3.6e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—PIK3CA—liver cancer	2.84e-07	3.6e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—PIK3CA—liver cancer	2.83e-07	3.59e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—STAT3—liver cancer	2.83e-07	3.59e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—ALB—liver cancer	2.82e-07	3.58e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—AKT1—liver cancer	2.82e-07	3.57e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CDKN1B—liver cancer	2.81e-07	3.57e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—HRAS—liver cancer	2.81e-07	3.56e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—AKT1—liver cancer	2.81e-07	3.56e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—HRAS—liver cancer	2.77e-07	3.51e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CASP3—liver cancer	2.76e-07	3.5e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—HRAS—liver cancer	2.76e-07	3.5e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL2—liver cancer	2.75e-07	3.49e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—PIK3CA—liver cancer	2.75e-07	3.49e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TP53—liver cancer	2.74e-07	3.48e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—KRAS—liver cancer	2.72e-07	3.46e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—MYC—liver cancer	2.72e-07	3.45e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—RAF1—liver cancer	2.72e-07	3.45e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—TGFB1—liver cancer	2.72e-07	3.44e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IL6—liver cancer	2.69e-07	3.41e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCND1—liver cancer	2.69e-07	3.41e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP2E1—liver cancer	2.68e-07	3.4e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—JUN—liver cancer	2.68e-07	3.4e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—VEGFA—liver cancer	2.67e-07	3.39e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TP53—liver cancer	2.66e-07	3.38e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CTNNB1—liver cancer	2.66e-07	3.37e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MTOR—liver cancer	2.66e-07	3.37e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3CB—liver cancer	2.66e-07	3.37e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IL6—liver cancer	2.65e-07	3.36e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—STAT3—liver cancer	2.65e-07	3.36e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—IL6—liver cancer	2.64e-07	3.35e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—AKT1—liver cancer	2.64e-07	3.34e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MYC—liver cancer	2.63e-07	3.33e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—HRAS—liver cancer	2.63e-07	3.33e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TGFB1—liver cancer	2.62e-07	3.32e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—HRAS—liver cancer	2.62e-07	3.32e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—PIK3CA—liver cancer	2.61e-07	3.31e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MMP9—liver cancer	2.61e-07	3.31e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CDKN1A—liver cancer	2.6e-07	3.29e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—HRAS—liver cancer	2.55e-07	3.23e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MAPK8—liver cancer	2.54e-07	3.22e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—KRAS—liver cancer	2.52e-07	3.19e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IL6—liver cancer	2.51e-07	3.19e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYCS—liver cancer	2.51e-07	3.19e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL6—liver cancer	2.5e-07	3.18e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—PIK3CA—liver cancer	2.5e-07	3.17e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CDKN1B—liver cancer	2.49e-07	3.16e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CB—liver cancer	2.49e-07	3.16e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—AKT1—liver cancer	2.48e-07	3.14e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GGT1—liver cancer	2.46e-07	3.13e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GOT1—liver cancer	2.46e-07	3.13e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MYC—liver cancer	2.46e-07	3.12e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TGFB1—liver cancer	2.45e-07	3.11e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CG—liver cancer	2.45e-07	3.11e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—AKT1—liver cancer	2.44e-07	3.1e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CASP3—liver cancer	2.44e-07	3.1e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IL6—liver cancer	2.44e-07	3.09e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL2—liver cancer	2.44e-07	3.09e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—AKT1—liver cancer	2.44e-07	3.09e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—KRAS—liver cancer	2.43e-07	3.08e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—HRAS—liver cancer	2.42e-07	3.06e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCND1—liver cancer	2.38e-07	3.01e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—JUN—liver cancer	2.37e-07	3.01e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PPARG—liver cancer	2.37e-07	3e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CTNNB1—liver cancer	2.35e-07	2.99e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—VEGFA—liver cancer	2.34e-07	2.97e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—AKT1—liver cancer	2.32e-07	2.94e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—STAT3—liver cancer	2.32e-07	2.94e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—HRAS—liver cancer	2.32e-07	2.94e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—IL6—liver cancer	2.31e-07	2.93e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—PIK3CA—liver cancer	2.31e-07	2.93e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—AKT1—liver cancer	2.31e-07	2.93e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MMP9—liver cancer	2.31e-07	2.93e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CDKN1A—liver cancer	2.3e-07	2.92e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—KRAS—liver cancer	2.27e-07	2.88e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—AKT1—liver cancer	2.25e-07	2.85e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MAPK8—liver cancer	2.24e-07	2.85e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PIK3CA—liver cancer	2.23e-07	2.83e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL6—liver cancer	2.22e-07	2.81e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GSTP1—liver cancer	2.21e-07	2.81e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—HMOX1—liver cancer	2.18e-07	2.77e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TP53—liver cancer	2.16e-07	2.74e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CD—liver cancer	2.16e-07	2.73e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MYC—liver cancer	2.15e-07	2.73e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TGFB1—liver cancer	2.15e-07	2.72e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—HRAS—liver cancer	2.14e-07	2.71e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—AKT1—liver cancer	2.13e-07	2.7e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ALB—liver cancer	2.13e-07	2.7e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PIK3CA—liver cancer	2.09e-07	2.65e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—VEGFA—liver cancer	2.07e-07	2.63e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—HRAS—liver cancer	2.06e-07	2.62e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—STAT3—liver cancer	2.05e-07	2.6e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—IL6—liver cancer	2.05e-07	2.6e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—AKT1—liver cancer	2.05e-07	2.59e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GSTM1—liver cancer	2.03e-07	2.58e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TP53—liver cancer	2.02e-07	2.56e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—KRAS—liver cancer	1.99e-07	2.52e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL6—liver cancer	1.98e-07	2.5e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—HRAS—liver cancer	1.93e-07	2.45e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP1A1—liver cancer	1.93e-07	2.45e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MYC—liver cancer	1.91e-07	2.42e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TGFB1—liver cancer	1.9e-07	2.41e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—AKT1—liver cancer	1.89e-07	2.39e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CB—liver cancer	1.88e-07	2.38e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL6—liver cancer	1.85e-07	2.34e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PIK3CA—liver cancer	1.83e-07	2.32e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—AKT1—liver cancer	1.82e-07	2.31e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—MTHFR—liver cancer	1.8e-07	2.28e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TP53—liver cancer	1.77e-07	2.24e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PPARA—liver cancer	1.76e-07	2.24e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—KRAS—liver cancer	1.76e-07	2.23e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—AKT1—liver cancer	1.71e-07	2.16e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—HRAS—liver cancer	1.69e-07	2.15e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL6—liver cancer	1.62e-07	2.05e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3CA—liver cancer	1.62e-07	2.05e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TP53—liver cancer	1.57e-07	1.99e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CA—liver cancer	1.52e-07	1.92e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CG—liver cancer	1.51e-07	1.92e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HRAS—liver cancer	1.5e-07	1.9e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—AKT1—liver cancer	1.49e-07	1.89e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PPARG—liver cancer	1.46e-07	1.85e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL6—liver cancer	1.43e-07	1.82e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CD—liver cancer	1.33e-07	1.68e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—AKT1—liver cancer	1.32e-07	1.68e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ALB—liver cancer	1.31e-07	1.66e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—AKT1—liver cancer	1.24e-07	1.57e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CB—liver cancer	1.16e-07	1.47e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CA—liver cancer	1.15e-07	1.45e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—AKT1—liver cancer	9.36e-08	1.19e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CA—liver cancer	7.06e-08	8.95e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—AKT1—liver cancer	5.76e-08	7.31e-07	CbGpPWpGaD
